Head-to-head · WeighScore
Genesis Health vs Zealthy
The verdict
Genesis Health takes it — 68.2/100 to 46.7/100.
Genesis Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Genesis Health is a telehealth platform offering compounded semaglutide and tirzepatide injections alongside brand-name Wegovy, Ozempic, and Zepbound.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Genesis Health | Zealthy |
|---|---|---|
| WeighScore | 68.2/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #150 | #496 |
| Semaglutide | $175/mo (starting dose, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | $235/mo (starting dose, compounded) | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | Coverage not published | 34 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #150 · C
Strengths
- Annual plan as low as $99/mo for semaglutide or $125/mo for tirzepatide
- Offers both compounded and brand-name GLP-1s (Wegovy, Ozempic, Zepbound) in one platform
- Includes health coaching, active community, and free expedited shipping on every plan
- LegitScript certified; medications sourced from audited, licensed US compounding pharmacies
- Same-day provider visits, personalized dosing, and 24/7 care team messaging
Where it loses points
- States served not publicly listed; telehealth coverage unconfirmed for all states
- Monthly starting price ($175 sema / $235 tirz) is mid-market without annual commitment
- Labs not disclosed or included in any published plan tier
- Brand-name GLP-1 pricing not published; insurance or coupon required
- Compounded medications are not FDA-approved
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.